vimarsana.com
Home
Live Updates
Samsung Bioepis to Present Post-hoc Analysis of Phase 3 : vi
Samsung Bioepis to Present Post-hoc Analysis of Phase 3 : vi
Samsung Bioepis to Present Post-hoc Analysis of Phase 3
Post-hoc analysis of Phase 3 study to highlight transfusion avoidance results of SB12 compared to reference eculizumab-treated groups INCHEON, Korea, May ...
Related Keywords
Spain ,
Madrid ,
Eculizumab Biosimilar ,
Younsoo Kim ,
Samsung Bioepis ,
Jihyun Han ,
Paola Russo ,
Hyejin Kim ,
Hus Laboratory Monitoring ,
Lifecycle Safety Team Leader At Samsung Bioepis ,
Linkedin ,
European Hematology Association ,
Laboratory Monitoring ,
Samsung Bioepis Co Ltd ,
European Union ,
European Medicines Agency ,
European Commission ,
Alexion Pharmaceuticals ,
Hybrid Congress ,
Vice President ,
Lifecycle Safety Team Leader ,
Transfusion Avoidance ,
Reference Eculizumab ,
Post Hoc Analysis ,
Pivotal Phase ,
Jun Ho Jang ,
Jihye Park ,
Product Characteristics ,
Soliris Product ,
Accessed May ,
Epysqli Product ,